Back to Search

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

  • Protocol Number: 202204103
  • Principal Investigator: Adkins, Douglas
  • Cancer Types: Head & Neck

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions